AXER-204 in Participants With Chronic Spinal Cord Injury
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This two-part trial will assess the safety, tolerability, pharmacokinetics, and efficacy of
AXER-204 administered by lumbar puncture and slow bolus infusion. Part 1 will evaluate the
safety, tolerability, and pharmacokinetics of single ascending doses of AXER-204. Part 2 will
evaluate the safety, tolerability, pharmacokinetics, and efficacy of repeated doses AXER-204
in comparison to placebo.